Journal
Blood Advances
Publication Date
2018
Volume
2
Issue
24
Inclusive Pages
3572-3580
Document Type
Open Access Publication
DOI
10.1182/bloodadvances.2018019661.
Rights and Permissions
Rampal, R. K., Mascarenhas, J. O., Kosiorek, H. E., Price, L., Berenzon, D., Hexner, E., Abboud, C. N., Kremyanskaya, M., Weinberg, R. S., Salama, M. E., Menghrajani, K., Najfeld, V., Sandy, L., Heaney, M. L., Levine, R. L., Mesa, R. A., Dueck, A. C., Goldberg, J. D., & Hoffman, R. (2018). Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms. Blood Advances, 2(24), 3572-3580. Accessed January 04, 2019. https://doi.org/10.1182/bloodadvances.2018019661.
Recommended Citation
Abboud, Camille N., "Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms." Blood Advances. 2, 24. 3572-3580. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/7378
